Laura Chico
Stock Analyst at Wedbush
(3.01)
# 1,318
Out of 4,902 analysts
228
Total ratings
39.87%
Success rate
0.73%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Neutral | $35 → $34 | $27.65 | +22.97% | 13 | Jul 14, 2025 | |
| MAZE Maze Therapeutics | Initiates: Outperform | $17 | $16.47 | +3.25% | 1 | Jul 8, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $16 → $18 | $8.59 | +109.55% | 1 | Jun 30, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $17 → $15 | $3.28 | +357.32% | 2 | Jun 24, 2025 | |
| LEN Lennar | Reiterates: Neutral | $130 | $109.57 | +18.65% | 1 | Jun 18, 2025 | |
| BIIB Biogen | Reiterates: Neutral | $121 | $128.10 | -5.54% | 18 | Jun 12, 2025 | |
| PHVS Pharvaris | Reiterates: Outperform | $27 | $22.81 | +18.37% | 6 | Jun 5, 2025 | |
| VIGL Vigil Neuroscience | Downgrades: Neutral | $13 → $8 | $8.07 | -0.88% | 11 | May 22, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Outperform | $30 | $16.82 | +78.36% | 11 | May 16, 2025 | |
| GOSS Gossamer Bio | Reiterates: Outperform | $4 | $1.75 | +128.57% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $5.91 | +187.65% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $17 | $9.16 | +85.59% | 2 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $2.96 | +35.14% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $30 | $14.58 | +105.76% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $26 | $23.77 | +9.38% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $28 | $54.45 | -48.58% | 7 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $43 | $13.82 | +211.14% | 10 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $43 | $18.61 | +131.06% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $0.50 | +500.48% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $19.94 | +80.54% | 6 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $28 | $6.23 | +349.43% | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $20.17 | +43.78% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6 | $9.14 | -34.35% | 9 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $147 | $134.77 | +9.07% | 9 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $12 | $1.32 | +809.09% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $49 | $32.05 | +52.89% | 8 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $3.24 | +116.05% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $4.60 | +139.13% | 13 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $17.04 | +146.48% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $17 | $12.22 | +39.12% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.46 | +2,280.95% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $4.06 | +23.15% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $58.83 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $2.57 | +94.55% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $15.01 | +889.34% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $8.54 | +8,330.91% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $53.22 | +426.12% | 1 | Apr 21, 2017 |
Ultragenyx Pharmaceutical
Jul 14, 2025
Maintains: Neutral
Price Target: $35 → $34
Current: $27.65
Upside: +22.97%
Maze Therapeutics
Jul 8, 2025
Initiates: Outperform
Price Target: $17
Current: $16.47
Upside: +3.25%
BioCryst Pharmaceuticals
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $8.59
Upside: +109.55%
Larimar Therapeutics
Jun 24, 2025
Maintains: Outperform
Price Target: $17 → $15
Current: $3.28
Upside: +357.32%
Lennar
Jun 18, 2025
Reiterates: Neutral
Price Target: $130
Current: $109.57
Upside: +18.65%
Biogen
Jun 12, 2025
Reiterates: Neutral
Price Target: $121
Current: $128.10
Upside: -5.54%
Pharvaris
Jun 5, 2025
Reiterates: Outperform
Price Target: $27
Current: $22.81
Upside: +18.37%
Vigil Neuroscience
May 22, 2025
Downgrades: Neutral
Price Target: $13 → $8
Current: $8.07
Upside: -0.88%
Travere Therapeutics
May 16, 2025
Reiterates: Outperform
Price Target: $30
Current: $16.82
Upside: +78.36%
Gossamer Bio
May 16, 2025
Reiterates: Outperform
Price Target: $4
Current: $1.75
Upside: +128.57%
May 16, 2025
Maintains: Outperform
Price Target: $18 → $17
Current: $5.91
Upside: +187.65%
May 15, 2025
Reiterates: Outperform
Price Target: $17
Current: $9.16
Upside: +85.59%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $2.96
Upside: +35.14%
May 7, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $14.58
Upside: +105.76%
May 7, 2025
Maintains: Neutral
Price Target: $34 → $26
Current: $23.77
Upside: +9.38%
May 5, 2025
Maintains: Underperform
Price Target: $26 → $28
Current: $54.45
Upside: -48.58%
Apr 21, 2025
Maintains: Outperform
Price Target: $43
Current: $13.82
Upside: +211.14%
Mar 14, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $18.61
Upside: +131.06%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $0.50
Upside: +500.48%
Mar 12, 2025
Reiterates: Outperform
Price Target: $36
Current: $19.94
Upside: +80.54%
Mar 12, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $6.23
Upside: +349.43%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $20.17
Upside: +43.78%
Feb 12, 2025
Reiterates: Neutral
Price Target: $6
Current: $9.14
Upside: -34.35%
Feb 7, 2025
Maintains: Outperform
Price Target: $157 → $147
Current: $134.77
Upside: +9.07%
Nov 8, 2024
Maintains: Outperform
Price Target: $19 → $12
Current: $1.32
Upside: +809.09%
Aug 9, 2024
Maintains: Outperform
Price Target: $50 → $49
Current: $32.05
Upside: +52.89%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $3.24
Upside: +116.05%
Aug 2, 2024
Reiterates: Outperform
Price Target: $11
Current: $4.60
Upside: +139.13%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $17.04
Upside: +146.48%
Jul 11, 2024
Reiterates: Outperform
Price Target: $17
Current: $12.22
Upside: +39.12%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.46
Upside: +2,280.95%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $4.06
Upside: +23.15%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $58.83
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $2.57
Upside: +94.55%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $15.01
Upside: +889.34%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $8.54
Upside: +8,330.91%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $53.22
Upside: +426.12%